13 Feb 2017 Helsinki - In the laboratories of Institute of Molecular Medicine Finland (FIMM), drug testing is done ex vivo. That is, various leukemia drugs are tested with patient samples instead of the patients themselves. This enables the researchers to test different drug combinations efficiently and without burdening the patient.
Jing Tang, a researcher working in FIMM, wants to integrate drug screening and genomic profiling data in order to find personalized treatment options for leukemia.
"Then, based on the patients genetic background, we would know what might be the best drug combination", Jing Tang clarified.
With their idea, Jing Tang and a cross-disciplinary team of researchers in medicine, biology and informatics from University of Helsinki and University of Turku were chosen as one of the semifinals of Helsinki Challenge, science-based idea competition and accelerator programme organised by University of Helsinki and several Finnish partner universities.
After several years of experiments the bottleneck in the project is data integration. Therefore it is integral to include informatics.
"We will develop a series of computational methods for drug combination prediction, modelling and data analysis. These methods will offer an improved efficiency to identify more effective combinatorial treatments for personalized medicine", Jing Tang stated.
In the future, it may be possible to apply the same model for personalized treatment of other cancer types and illnesses as well.
In order to make personalized medicine more accessible and applicable Jing Tang and his team intend to take Helsinki Challenge as an opportunity to build a larger community around the topic.
"For this we need people from various fields with the same aim - we want to give the patient the right drug the right time. That will also save costs."